Mirum Pharmaceuticals Inc. announced that its preliminary unaudited net product sales for 2025 are approximately $520 million, exceeding the upper end of its guidance. For 2026, the company expects global net product sales to be between $630 million and $650 million, reflecting continued strong commercial growth. The financial outlook highlights significant year-over-year growth and underscores the company’s momentum in both commercial performance and pipeline advancement.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mirum Pharmaceuticals Inc. published the original content used to generate this news brief on January 12, 2026, and is solely responsible for the information contained therein.
Comments